Novo Nordisk Promoted an Internal Executive and Consolidated R&D to Speed Up Decision-Making.

On August 7, 2025, Maziar Mike Doustdar became CEO of Novo Nordisk after running the company's International Operations for the past decade. He was promoted from within, not hired from outside. The Novo Nordisk Foundation, which controls the voting, endorsed the board's decision and the entire board supported it unanimously.

But the structure matters more than the succession itself.

On the same day, Novo Nordisk merged its Research & Early Development division with its Development division into a single R&D unit. Two functions that had reported to the CEO separately now report as one. Marcus Schindler, the old Chief Scientific Officer of Research & Early Development, retired. Martin Holst Lange, who was heading Development, got promoted to Chief Scientific Officer of the merged unit.

What this means: one person now owns the entire pipeline from early science to launch. Before, a scientist running early work could say no to a development executive, and vice versa. Now there is no one between them. Decisions move through a single channel instead of competing channels.

Emil Kongshøj Larsen moved into Doustdar's old job running International Operations. This was a promotion from regional leadership into a larger portfolio. It reads as deliberate succession planning for a role Doustdar was leaving.

Contrast this to May, when the Foundation forced out the previous CEO and the foundation chair had to join the board as an observer to increase its grip on the company. This time, the Foundation endorsed the choice. The board was unified. There was an internal and external search. The company had already signaled in May that succession was coming. The successor had a decade of internal track record at scale.

What I would look for: whether Doustdar keeps the merged R&D structure or splits it back apart. Whether Larsen gets reappointed to International Operations when his term is up or whether the role gets reorganized again. Whether the Foundation stays hands-off or continues moving observers onto the board.

The bigger lesson is that planned succession, where the shareholder and board agree beforehand, looks completely different from succession under duress.